Genes for elite power and sprint performance: ACTN3 leads the way

Sports Medicine

Volumn 43, Issue 9, 2013, Pages 803-817

  Eynon, Nir ^a   Hanson, Erik D ^a   Lucia, Alejandro ^b   Houweling, Peter J ^c,d   Garton, Fleur ^c,d   North, Kathryn N ^c,d,e   Bishop, David J ^a  

^a VICTORIA UNIVERSITY   (Australia)

^b UNIVERSIDAD EUROPEA DE MADRID   (Spain)

^c CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^d University of Sydney   (Australia)

^e ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACTININ; ACTN3 PROTEIN, HUMAN; ADENOSINE MONOPHOSPHATE DEAMINASE; AMPD1 PROTEIN, HUMAN; ANGIOTENSINOGEN; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA;

ANIMAL; ATHLETIC PERFORMANCE; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HUMAN; MUSCLE STRENGTH; PHYSIOLOGY; REVIEW; RUNNING; SKELETAL MUSCLE;

ACTININ; AMP DEAMINASE; ANGIOTENSINOGEN; ANIMALS; ATHLETIC PERFORMANCE; GENOTYPE; HUMANS; INTERLEUKIN-6; MUSCLE STRENGTH; MUSCLE, SKELETAL; NITRIC OXIDE SYNTHASE TYPE III; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC; PPAR ALPHA; RUNNING;

EID: 84883216505     PISSN: 01121642     EISSN: 11792035     Source Type: Journal    
DOI: 10.1007/s40279-013-0059-4     Document Type: Review

References (122)

1. Macarthur DG, North KN. Genes and human elite athletic performance. Hum Genet. 2005;116(5):331-9.
2. Druzhevskaya AM, Ahmetov II, Astratenkova IV, et al. Association of the ACTN3 R577X polymorphism with power athlete status in Russians. Eur J Appl Physiol. 2008;103(6):631-4.
3. Eynon N, Ruiz JR, Oliveira J, et al. Genes and elite athletes: a roadmap for future research. J Physiol. 2011;589(13):3063-70.
4. Stubbe JH, Boomsma DI, Vink JM, et al. Genetic influences on exercise participation in 37,051 twin pairs from seven countries. PloS one. 2006;1:e22.
5. De Moor MH, Spector TD, Cherkas LF, et al. Genome-wide linkage scan for athlete status in 700 British female DZ twin pairs. Twin Res Hum Genet. 2007;10(6):812-20.
6. Bouchard C, Sarzynski MA, Rice TK, et al. Genomic predictors of the maximal O uptake response to standardized exercise training programs. J Appl Physiol. 2011;110(5):1160-70.
7. Peeters MW, Thomis MA, Beunen GP, et al. Genetics and sports: an overview of the pre-molecular biology era. Med Sport Sci. 2009;54:28-42.
8. Calvo M, Rodas G, Vallejo M, et al. Heritability of explosive power and anaerobic capacity in humans. Eur J Appl Physiol. 2002;86(3):218-25.
9. Hagberg JM, Rankinen T, Loos RJ, et al. Advances in exercise, fitness, and performance genomics in 2010. Med Sci Sports Exerc. 2011;43(5):743-52.
10. Rankinen T, Roth SM, Bray MS, et al. Advances in exercise, fitness, and performance genomics. Med Sci Sports Exerc. 2010;42(5):835-46.
11. Roth SM, Rankinen T, Hagberg JM, et al. Advances in exercise, fitness, and performance genomics in 2011. Med Sci Sports Exerc. 2012;44(5):809-17.
12. Ahmetov II, Williams AG, Popov DV, et al. The combined impact of metabolic gene polymorphisms on elite endurance athlete status and related phenotypes. Hum Genet. 2009;126(6):751-61.
13. Ruiz JR, Gomez-Gallego F, Santiago C, et al. Is there an optimum endurance polygenic profile? J Physiol. 2009;587(Pt 7):1527-34.
14. Mole PA, Oscai LB, Holloszy JO. Adaptation of muscle to exercise: increase in levels of palmityl Coa synthetase, carnitine palmityltransferase, and palmityl Coa dehydrogenase, and in the capacity to oxidize fatty acids. J Clin Invest. 1971;50(11):2323-30.
15. Spencer MR, Gastin PB. Energy system contribution during 200- to 1500-m running in highly trained athletes. Med Sci Sports Exerc. 2001;33(1):157-62.
16. Ahmetov, II, Druzhevskaya AM, Lyubaeva EV, et al. The dependence of preferred competitive racing distance on muscle fibre type composition and ACTN3 genotype in speed skaters. Exp Physiol. 2011;96(12):1302-10
17. Van Damme R, Wilson RS, Vanhooydonck B, et al. Performance constraints in decathletes. Nature. 2002;415(6873):755-6.
18. Seeman E, Hopper JL, Young NR, et al. Do genetic factors explain associations between muscle strength, lean mass, and bone density? A twin study. Am J Physiol. 1996;270(2 Pt 1):E320-7.
19. Thomis MA, Beunen GP, Maes HH, et al. Strength training: importance of genetic factors. Med Sci Sports Exerc. 1998;30(5):724-31.
20. Thomis MA, Beunen GP, Van Leemputte M, et al. Inheritance of static and dynamic arm strength and some of its determinants. Acta Physiol Scand. 1998;163(1):59-71.
21. MacArthur DG, North KN. A gene for speed? The evolution and function of alpha-actinin-3. Bioessays. 2004;26(7):786-95.
22. Mills M, Yang N, Weinberger R, et al. Differential expression of the actin-binding proteins, alpha-actinin-2 and -3, in different species: implications for the evolution of functional redundancy. Hum Mol Genet. 2001;10(13):1335-46.
23. North KN, Yang N, Wattanasirichaigoon D, et al. A common nonsense mutation results in alpha-actinin-3 deficiency in the general population. Nat Genet. 1999;21(4):353-4.
24. Yang N, MacArthur DG, Gulbin JP, et al. ACTN3 genotype is associated with human elite athletic performance. Am J Hum Genet. 2003;73(3):627-31.
25. Eynon N, Duarte JA, Oliveira J, et al. ACTN3 R577X polymorphism and Israeli top-level athletes. Int J Sports Med. 2009;30(9):695-8.
26. Niemi AK, Majamaa K. Mitochondrial DNA and ACTN3 genotypes in Finnish elite endurance and sprint athletes. Eur J Hum Genet. 2005;13(8):965-9.
27. Doring FE, Onur S, Geisen U, et al. ACTN3 R577X and other polymorphisms are not associated with elite endurance athlete status in the Genathlete study. J Sports Sci. 2010;28(12):1355-9.
28. Muniesa CA, Gonzalez-Freire M, Santiago C, et al. World-class performance in lightweight rowing: is it genetically influenced? A comparison with cyclists, runners and non-athletes. Br J Sports Med. 2010;44(12):898-901.
29. Saunders CJ, September AV, Xenophontos SL, et al. No association of the ACTN3 gene R577X polymorphism with endurance performance in Ironman Triathlons. Ann Hum Genet. 2007;71(Pt 6):777-81.
30. Scott RA, Irving R, Irwin L, et al. ACTN3 and ACE genotypes in elite Jamaican and US sprinters. Med Sci Sports Exerc. 2010;42(1):107-12.
31. Yang N, MacArthur DG, Wolde B, et al. The ACTN3 R577X polymorphism in East and West African athletes. Med Sci Sports Exerc. 2007;39(11):1985-8.
32. Ruiz JR, Fernández del Valle M, Verde Z, et al. ACTN3 R577X polymorphism does not influence explosive leg muscle power in elite volleyball players. Scand J Med Sci Sports. 2011;21(6):e34-41.
33. Papadimitriou ID, Papadopoulos C, Kouvatsi A, et al. The ACTN3 gene in elite Greek track and field athletes. Int J Sports Med. 2008;29(4):352-5.
34. Gineviciene V, Pranculis A, Jakaitiene A, et al. Genetic variation of the human ACE and ACTN3 genes and their association with functional muscle properties in Lithuanian elite athletes. Medicina. 2011;47(5):284-90.
35. Roth SM, Walsh S, Liu D, et al. The ACTN3 R577X nonsense allele is under-represented in elite-level strength athletes. Eur J Hum Genet. 2008;16(3):391-4.
36. Eynon N, Ruiz JR, Femia P, et al. The ACTN3 R577X polymorphism across three groups of elite male European athletes. PloS one. 2012;7(8):e43132.
37. Chiu LL, Wu YF, Tang MT, et al. ACTN3 genotype and swimming performance in Taiwan. Int J Sports Med. 2011;32(6):476-80.
38. Eynon N, Alves AJ, Meckel Y, et al. Is the interaction between HIF1A P582S and ACTN3 R577X determinant for power/sprint performance? Metabolism. 2010;59(6):861-5.
39. Eynon N, Alves AJ, Yamin C, et al. Is there an ACE ID - ACTN3 R577X polymorphisms interaction that influences sprint performance? Int J Sports Med. 2009;30(12):888-91.
40. Ruiz JR, Arteta D, Buxens A, et al. Can we identify a power-oriented polygenic profile? J Appl Physiol. 2010;108(3):561-6.
41. MacArthur DG, Seto JT, Raftery JM, et al. Loss of ACTN3 gene function alters mouse muscle metabolism and shows evidence of positive selection in humans. Nat Genet. 2007;39(10):1261-5.
42. MacArthur DG, Seto JT, Chan S, et al. An Actn3 knockout mouse provides mechanistic insights into the association between alpha-actinin-3 deficiency and human athletic performance. Hum Mol Genet. 2008;17(8):1076-86.
43. Chan S, Seto JT, MacArthur DG, et al. A gene for speed: contractile properties of isolated whole EDL muscle from an alpha-actinin-3 knockout mouse. Am J Physiol Cell Physiol. 2008;295(4):C897-904.
44. Berman Y, North KN. A gene for speed: the emerging role of alpha-actinin-3 in muscle metabolism. Physiology. 2010;25(4):250-9.
45. Vincent B, De Bock K, Ramaekers M, et al. ACTN3 (R577X) genotype is associated with fiber type distribution. Physiol Genomics. 2007;32(1):58-63.
46. Rigat B, Hubert C, Alhenc-Gelas F, et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990;86(4):1343-6.
47. Danser AH, Schalekamp MA, Bax WA, et al. Angiotensin-converting enzyme in the human heart: effect of the deletion/insertion polymorphism. Circulation. 1995;92(6):1387-8.
48. Myerson S, Hemingway H, Budget R, et al. Human angiotensin I-converting enzyme gene and endurance performance. J Appl Physiol. 1999;87(4):1313-6.
49. Costa AM, Silva AJ, Garrido ND, et al. Association between ACE D allele and elite short distance swimming. Eur J Appl Physiol. 2009;106(6):785-90.
50. Juffer P, Furrer R, Gonzalez-Freire M, et al. Genotype distributions in top-level soccer players: a role for ACE? Int J Sports Med. 2009;30(5):387-92.
51. Nazarov IB, Woods DR, Montgomery HE, et al. The angiotensin converting enzyme I/D polymorphism in Russian athletes. Eur J Hum Genet. 2001;9(10):797-801.
52. Woods D, Hickman M, Jamshidi Y, et al. Elite swimmers and the D allele of the ACE I/D polymorphism. Hum Genet. 2001;108(3):230-2.
53. Papadimitriou ID, Papadopoulos C, Kouvatsi A, et al. The ACE I/D polymorphism in elite Greek track and field athletes. J Sports Med Phys Fitness. 2009;49(4):459-63.
54. Sessa F, Chetta M, Petito A, et al. Gene polymorphisms and sport attitude in Italian athletes. Genet Test Mol Biomarkers. 2011;15(4):285-90.
55. Amir O, Amir R, Yamin C, et al. The ACE deletion allele is associated with Israeli elite endurance athletes. Exp Physiol. 2007;92(5):881-6.
56. Kim CH, Cho JY, Jeon JY, et al. ACE DD genotype is unfavorable to Korean short-term muscle power athletes. Int J Sports Med. 2010;31(1):65-71.
57. Zoossmann-Diskin A. The association of the ACE gene and elite athletic performance in Israel may be an artifact. Exp Physiol. 2008;93(11):1220 (author reply 1).
58. Montgomery HE, Clarkson P, Dollery CM, et al. Association of angiotensin-converting enzyme gene I/D polymorphism with change in left ventricular mass in response to physical training. Circulation. 1997;96(3):741-7.
59. Sadoshima J, Xu Y, Slayter HS, et al. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell. 1993;75(5):977-84.
60. Silva GJ, Moreira ED, Pereira AC, et al. ACE gene dosage modulates pressure-induced cardiac hypertrophy in mice and men. Physiol Genomics. 2006;27(3):237-44.
61. Berk BC, Vekshtein V, Gordon HM, et al. Angiotensin II-stimulated protein synthesis in cultured vascular smooth muscle cells. Hypertension. 1989;13(4):305-14.
62. Geisterfer AA, Peach MJ, Owens GK. Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res. 1988;62(4):749-56.
63. Gordon SE, Davis BS, Carlson CJ, et al. ANG II is required for optimal overload-induced skeletal muscle hypertrophy. Am J Physiol Endocrinol Metab. 2001;280(1):E150-9.
64. Westerkamp CM, Gordon SE. Angiotensin-converting enzyme inhibition attenuates myonuclear addition in overloaded slow-twitch skeletal muscle. Am J Physiol Regul Integr Comp Physiol. 2005;289(4):R1223-31.
65. Charbonneau DE, Hanson ED, Ludlow AT, et al. ACE genotype and the muscle hypertrophic and strength responses to strength training. Med Sci Sports Exerc. 2008;40(4):677-83.
66. Folland J, Leach B, Little T, et al. Angiotensin-converting enzyme genotype affects the response of human skeletal muscle to functional overload. Exp Physiol. 2000;85(5):575-9.
67. Zhang B, Tanaka H, Shono N, et al. The I allele of the angiotensin-converting enzyme gene is associated with an increased percentage of slow-twitch type I fibers in human skeletal muscle. Clin Genet. 2003;63(2):139-44.
68. Zhang B, Shono N, Fan P, et al. Histochemical characteristics of soleus muscle in angiotensin-converting enzyme gene knockout mice. Hypertens Res. 2005;28(8):681-8.
69. Bae JS, Kang BY, Lee KO, et al. Genetic variation in the renin-angiotensin system and response to endurance training. Med Princ Pract. 2007;16(2):142-6.
70. Karjalainen J, Kujala UM, Stolt A, et al. Angiotensinogen gene M235T polymorphism predicts left ventricular hypertrophy in endurance athletes. J Am Coll Cardiol. 1999;34(2):494-9.
71. Gomez-Gallego F, Santiago C, Gonzalez-Freire M, et al. The C allele of the AGT Met235Thr polymorphism is associated with power sports performance. Appl Physiol Nutr Metab. 2009;34(6):1108-11.
72. Norman B, Sabina RL, Jansson E. Regulation of skeletal muscle ATP catabolism by AMPD1 genotype during sprint exercise in asymptomatic subjects. J Appl Physiol. 2001;91(1):258-64.
73. Rubio JC, Martin MA, Rabadan M, et al. Frequency of the C34T mutation of the AMPD1 gene in world-class endurance athletes: does this mutation impair performance? J Appl Physiol. 2005;98(6):2108-12.
74. Morisaki T, Gross M, Morisaki H, et al. Molecular basis of AMP deaminase deficiency in skeletal muscle. Proc Natl Acad Sci USA. 1992;89(14):6457-61.
75. Norman B, Glenmark B, Jansson E. Muscle AMP deaminase deficiency in 2% of a healthy population. Muscle Nerve. 1995;18(2):239-41.
76. Norman B, Mahnke-Zizelman DK, Vallis A, et al. Genetic and other determinants of AMP deaminase activity in healthy adult skeletal muscle. J Appl Physiol. 1998;85(4):1273-8.
77. Lucia A, Martin MA, Esteve-Lanao J, et al. C34T mutation of the AMPD1 gene in an elite white runner. Br J Sports Med. 2006;40(3):e7.
78. Fischer H, Esbjornsson M, Sabina RL, et al. AMP deaminase deficiency is associated with lower sprint cycling performance in healthy subjects. J Appl Physiol. 2007;103(1):315-22.
79. Cieszczyk P, Ostanek M, Leonska-Duniec A, et al. Distribution of the AMPD1 C34T polymorphism in Polish power-oriented athletes. J Sports Sci. 2012;30(1):31-5.
80. Petersen AM, Pedersen BK. The anti-inflammatory effect of exercise. J Appl Physiol. 2005;98(4):1154-62.
81. Fishman D, Faulds G, Jeffery R, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest. 1998;102(7):1369-76.
82. Terry CF, Loukaci V, Green FR. Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem. 2000;275(24):18138-44.
83. Bennermo M, Held C, Stemme S, et al. Genetic predisposition of the interleukin-6 response to inflammation: implications for a variety of major diseases? Clin Chem. 2004;50(11):2136-40.
84. Yamin C, Duarte JA, Oliveira JM, et al. IL6 (-174) and TNFA (-308) promoter polymorphisms are associated with systemic creatine kinase response to eccentric exercise. Eur J Appl Physiol. 2008;104(3):579-86.
85. Ruiz JR, Buxens A, Artieda M, et al. The -174 G/C polymorphism of the IL6 gene is associated with elite power performance. J Sci Med Sport. 2010;13(5):549-53.
86. Eynon N, Ruiz JR, Meckel Y, et al. Is the -174 C/G polymorphism of the IL6 gene associated with elite power performance? A replication study with two different Caucasian cohorts. Exp Physiol. 2011;96(2):156-62.
87. Cooke JP, Rossitch E Jr, Andon NA, et al. Flow activates an endothelial potassium channel to release an endogenous nitrovasodilator. J Clin Invest. 1991;88(5):1663-71.
88. Quyyumi AA, Dakak N, Andrews NP, et al. Contribution of nitric oxide to metabolic coronary vasodilation in the human heart. Circulation. 1995;92(3):320-6.
89. Heydemann A, McNally E. NO more muscle fatigue. J Clin Invest. 2009;119(3):448-50.
90. Hickner RC, Fisher JS, Ehsani AA, et al. Role of nitric oxide in skeletal muscle blood flow at rest and during dynamic exercise in humans. Am J Physiol. 1997;273(1 Pt 2):H405-10.
91. McConell GK, Kingwell BA. Does nitric oxide regulate skeletal muscle glucose uptake during exercise? Exerc Sport Sci Rev. 2006;34(1):36-41.
92. Nakayama M, Yasue H, Yoshimura M, et al. T-786->C mutation in the 5′-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation. 1999;99(22):2864-70.
93. Wang XL, Sim AS, Wang MX, et al. Genotype dependent and cigarette specific effects on endothelial nitric oxide synthase gene expression and enzyme activity. FEBS Lett. 2000;471(1):45-50.
94. Yoshimura M, Yasue H, Nakayama M, et al. A missense Glu298Asp variant in the endothelial nitric oxide synthase gene is associated with coronary spasm in the Japanese. Hum Genet. 1998;103(1):65-9.
95. Hand BD, McCole SD, Brown MD, et al. NOS3 gene polymorphisms and exercise hemodynamics in postmenopausal women. Int J Sports Med. 2006;27(12):951-8.
96. Rankinen T, Rice T, Perusse L, et al. NOS3 Glu298Asp genotype and blood pressure response to endurance training: the HERITAGE family study. Hypertension. 2000;36(5):885-9.
97. Gomez-Gallego F, Ruiz JR, Buxens A, et al. The -786 T/C polymorphism of the NOS3 gene is associated with elite performance in power sports. Eur J Appl Physiol. 2009;107(5):565-9.
98. Kawada S, Ishii N. Skeletal muscle hypertrophy after chronic restriction of venous blood flow in rats. Med Sci Sports Exerc. 2005;37(7):1144-50.
99. Smith LW, Smith JD, Criswell DS. Involvement of nitric oxide synthase in skeletal muscle adaptation to chronic overload. J Appl Physiol. 2002;92(5):2005-11.
100. Liang H, Ward WF. PGC-1alpha: a key regulator of energy metabolism. Adv Physiol Educ. 2006;30(4):145-51.
101. Jamshidi Y, Montgomery HE, Hense HW, et al. Peroxisome proliferator-activated receptor alpha gene regulates left ventricular growth in response to exercise and hypertension. Circulation. 2002;105(8):950-5.
102. Flavell DM, Jamshidi Y, Hawe E, et al. Peroxisome proliferator-activated receptor alpha gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease. Circulation. 2002;105(12):1440-5.
103. Ahmetov II, Mozhayskaya IA, Flavell DM, et al. PPARalpha gene variation and physical performance in Russian athletes. Eur J Appl Physiol. 2006;97(1):103-8.
104. Eynon N, Meckel Y, Sagiv M, et al. Do PPARGC1A and PPARalpha polymorphisms influence sprint or endurance phenotypes? Scand J Med Sci Sports. 2010;20(1):e145-50.
105. Rance KA, Johnstone AM, Murison S, et al. Plasma leptin levels are related to body composition, sex, insulin levels and the A55V polymorphism of the UCP2 gene. Int J Obes (Lond). 2007;31(8):1311-8.
106. Oktavianthi S, Trimarsanto H, Febinia CA, et al. Uncoupling protein 2 gene polymorphisms are associated with obesity. Cardiovasc Diabetol. 2012;11(1):41.
107. Martinez-Hervas S, Mansego ML, de Marco G, et al. Polymorphisms of the UCP2 gene are associated with body fat distribution and risk of abdominal obesity in Spanish population. Eur J Clin Invest. 2012;42(2):171-8.
108. Moran CN, Yang N, Bailey ME, et al. Association analysis of the ACTN3 R577X polymorphism and complex quantitative body composition and performance phenotypes in adolescent Greeks. Eur J Hum Genet. 2007;15(1):88-93.
109. Williams AG, Folland JP. Similarity of polygenic profiles limits the potential for elite human physical performance. J Physiol. 2008;586(1):113-21.
110. Buxens A, Ruiz JR, Arteta D, et al. Can we predict top-level sports performance in power vs endurance events? A genetic approach. Scand J Med Sci Sports. 2011;21(4):570-9.
111. Clarkson PM, Devaney JM, Gordish-Dressman H, et al. ACTN3 genotype is associated with increases in muscle strength in response to resistance training in women. J Appl Physiol. 2005;99(1):154-63.
112. Pimenta EM, Coelho DB, Cruz IR, et al. The ACTN3 genotype in soccer players in response to acute eccentric training. Eur J Appl Physiol. 2012;112(4):1495-503.
113. Seto JT, Chan S, Turner N, et al. The effect of alpha-actinin-3 deficiency on muscle aging. Exp Gerontol. 2011;46(4):292-302.
114. Alfred T, Ben-Shlomo Y, Cooper R, et al. ACTN3 genotype, athletic status, and life course physical capability: meta-analysis of the published literature and findings from nine studies. Hum Mutat. 2011;32(9):1008-18.
115. Delmonico MJ, Zmuda JM, Taylor BC, et al. Association of the ACTN3 genotype and physical functioning with age in older adults. J Gerontol A Biol Sci Med Sci. 2008;63(11):1227-34.
116. Garatachea N, Fiuza-Luces C, Torres-Luque G, et al. Single and combined influence of ACE and ACTN3 genotypes on muscle phenotypes in octogenarians. Eur J Appl Physiol. 2012;112(7):2409-20.
117. Seto JT, Lek M, Quinlan KG, et al. Deficiency of alpha-actinin-3 is associated with increased susceptibility to contraction-induced damage and skeletal muscle remodeling. Hum Mol Genet. 2011;20(15):2914-27.
118. Clarkson PM, Hoffman EP, Zambraski E, et al. ACTN3 and MLCK genotype associations with exertional muscle damage. J Appl Physiol. 2005;99(2):564-9.
119. MacArthur DG, Balasubramanian S, Frankish A, et al. A systematic survey of loss-of-function variants in human protein-coding genes. Science. 2012;335(6070):823-8.
120. Hong E, Park J. Sample size and statistical power calculations. Genomics Inform. 2012;10(2):117-22.
121. Santiago C, Gonzalez-Freire M, Serratosa L, et al. ACTN3 genotype in professional soccer players. Br J Sports Med. 2008;42(1):71-3.
122. Official Oympic Games 2012 Website. Men's maraton online. http://www.london2012.com/athletics/event/men-marathon/index.html. Accessed 29 Apr 2013.